Heron Therapeutics, Inc

(NASDAQ:HRTX)

Latest On Heron Therapeutics, Inc (HRTX):

Date/Time Type Description Signal Details
2023-05-13 00:29 ESTNewsHeron stock slumps ~35% amid quarterly misses on both linesN/A
2023-05-12 10:15 ESTNewsHeron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 20:40 ESTNewsHeron Therapeutics GAAP EPS of -$0.27 misses by $0.07, revenue of $29.62M misses by $0.07MN/A
2023-05-11 05:36 ESTNewsHeron Therapeutics Q1 2023 Earnings PreviewN/A
2023-04-21 21:15 ESTNewsCleaning The House May Not Solve Heron Therapeutics' ProblemsN/A
2023-04-03 22:18 ESTNewsHeron Therapeutics picks industry veteran as CEO, elects new board chairmanN/A
2023-03-24 11:39 ESTNewsHeron Therapeutics, Inc. 2022 Q4 - Results - Earnings Call PresentationN/A
2023-03-24 11:39 ESTNewsHeron Therapeutics, Inc. (HRTX) Q4 2022 Earnings Call TranscriptN/A
2023-03-24 11:38 ESTNewsHeron stock falls ~10% as headwinds for Zynrelef label, device delivery lingerN/A
2023-03-23 20:00 ESTNewsHeron Therapeutics GAAP EPS of -$0.17 beats by $0.15, revenue of $30.03M beats by $2.79MN/A
2023-03-23 03:36 ESTNewsHeron Therapeutics Q4 2022 Earnings PreviewN/A
2023-03-07 20:17 ESTNewsHeron Therapeutics (HRTX) presents at 2023 Cowen Conference - SlideshowN/A
2023-02-22 13:47 ESTNewsHeron gains on agreement with Rubric Capital and Velan CapitalN/A
2023-02-06 18:36 ESTNewsHeron climbs 14% as Rubric Capital discloses ~10% stakeN/A
2022-12-29 18:57 ESTNewsHeron spikes on FDA filing to expand label for pain therapyN/A
2022-12-20 13:03 ESTNewsHeron Therapeutics: Struggling Unsuccessfully With Its Slate Of Approved ProductsN/A
2022-11-09 06:53 ESTNewsHeron Therapeutics reports Q3 results, affirms FY oncology care franchise revenue guidanceN/A
2022-11-09 06:53 ESTNewsHeron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Call TranscriptN/A
2022-11-07 19:56 ESTNewsHeron Therapeutics Q3 2022 Earnings PreviewN/A
2022-09-20 17:29 ESTNewsHeron Therapeutics Is Not Out Of The Woods YetN/A
2022-09-17 04:36 ESTNewsHeron wins FDA nod for post-operative agent to address nausea and vomitingN/A
2022-08-10 01:17 ESTNewsHeron Therapeutics GAAP EPS of -$0.55 misses by $0.05, revenue of $27.63M beats by $2.98MN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics to raise $76.5M in stock and warrants offeringN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics rises 16% on Q2 revenue beat, raises 2022 sales forecastN/A
2022-08-10 01:16 ESTNewsHeron Therapeutics, Inc.'s (HRTX) CEO Barry Quart on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 03:30 ESTNewsHeron Therapeutics Q2 2022 Earnings PreviewN/A
2022-06-30 11:35 ESTNewsHeron Therapeutics proposes 34% cut in workforce as part of cost reduction planN/A
2022-05-10 06:55 ESTNewsHeron Therapeutics GAAP EPS of -$0.63 misses by $0.15, revenue of $23.46M beats by $0.85MN/A
2022-05-10 06:54 ESTNewsHeron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-13 18:27 ESTNewsHeron Therapeutics (HRTX) Presents At 21st Annual Needham Virtual Healthcare Conference - SlideshowN/A
2022-04-01 07:21 ESTNewsHeron Therapeutics: Cash Is A Problem AgainN/A
2022-03-17 11:23 ESTNewsHeron Therapeutics wins Health Canada approval of Zynrelef for postoperative painN/A
2022-03-05 00:01 ESTNewsHeron Therapeutics, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-03 12:39 ESTNewsHeron Therapeutics: Changing Strategy After Disappointing EarningsN/A
2022-03-02 01:58 ESTNewsHeron stock falls 21% as Q4 sales remain largely flat Y/YN/A
2022-03-01 07:42 ESTNewsHeron Therapeutics GAAP EPS of -$0.54 beats by $0.04, revenue of $20.66M misses by $5.11MN/A
2022-03-01 07:42 ESTNewsHeron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 11:50 ESTNewsHeron Therapeutics Q4 2021 Earnings PreviewN/A
2021-11-18 16:27 ESTNewsHeron Therapeutics submits HTX-019 application to FDA for prevention of PONVN/A
2021-11-04 10:25 ESTNewsHeron Therapeutics EPS beats by $0.10, misses on revenueN/A
2021-11-04 10:25 ESTNewsHeron Therapeutics, Inc. (HRTX) CEO Barry Quart on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 13:24 ESTNewsHeron Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-07 12:17 ESTNewsHeron Therapeutics: Looking For Signs Of The BottomN/A
2021-08-09 08:57 ESTNewsHeron Therapeutics EPS misses by $0.06, misses on revenueN/A
2021-07-23 00:53 ESTNewsHeron Therapeutics highlights promising data from ZYNRELEF postoperative pain trialsN/A
2021-07-21 11:40 ESTNewsHeron Therapeutics completes $150 million convertible debt financingN/A
2021-07-21 11:35 ESTNewsHeron Therapeutics files for 12.4M common stock offering from shareholderN/A
2021-07-21 11:15 ESTNewsHeron Therapeutics launches ZYNRELEF in the U.S.N/A
2021-04-04 15:43 ESTNewsMost-shorted U.S. stocks fall after rise earlier this year on GameStop squeezeN/A

About Heron Therapeutics, Inc (HRTX):

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX Quotes by TradingView

See Advanced Chart

General

  • Name Heron Therapeutics, Inc
  • Symbol HRTX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 223
  • Last Split Factor1:20
  • Last Split Date2014-01-13
  • Fiscal Year EndDecember
  • IPO Date1987-08-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.herontx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 16.77
  • Price/Book (Most Recent Quarter) 6.33
  • Enterprise Value Revenue 14.82
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.07
  • Next Year EPS Estimate -$1.08
  • Next Quarter EPS Estimate -$0.54
  • Profit Margin -256%
  • Operating Margin -251%
  • Return on Assets -32%
  • Return on Equity -71%
  • Revenue 88.64 million
  • Earnings Per Share -$2.56
  • Revenue Per Share $0.98
  • Gross Profit -120884000
  • Quarterly Earnings Growth -41.3%
View More

Highlights

  • Market Capitalization 1.43 billion
  • EBITDA -205512000
  • PEG Ratio -0.18
  • Analyst Target Price $34
  • Book Value Per Share $2.59
View More

Share Statistics

  • Shares Outstanding 91.4 million
  • Shares Float 79.79 million
  • % Held by Insiders 29%
  • % Held by Institutions 101.43%
  • Shares Short 20.15 million
  • Shares Short Prior Month 19.71 million
  • Short Ratio 21.47
  • Short % of Float 27%
  • Short % of Shares Outstanding 22%
View More

Technicals

  • Beta 1.45
  • 52 Week High $22.4
  • 52 Week Low $10.74
  • 50 Day Moving Average 18.15
  • 200 Day Moving Average 17.33
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Heron Therapeutics, Inc (HRTX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Heron Therapeutics, Inc (HRTX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-24$N/A-$0.68-$0.63-7.94%
2020-09-302020-11-05$N/A-$0.64-$0.62-3.56%
2020-06-302020-08-05$N/A-$0.61-$0.60-1.67%
2020-03-312020-05-06$N/A-$0.57-$0.6715.18%
2019-12-312020-03-02$35.08 million-$0.65-$0.56-15.72%
2019-09-302019-11-12$42.62 million-$0.42-$0.5827.8%
2019-06-302019-08-05$36.66 million-$0.63-$0.62-1.07%
2019-03-312019-05-09$31.6 million-$0.80-$0.50-61.39%
2018-12-312019-02-22$28.84 million-$0.63-$0.47-32.83%
2018-09-302018-11-07$19.79 million-$0.49-$0.44-11.72%
2018-06-302018-08-08$17.28 million-$0.54-$0.6820.08%
2018-03-312018-05-10$11.57 million-$0.81-$0.887.61%
2017-12-312018-02-27$10.05 million-$1.09-$0.79-37.97%
2017-09-302017-11-06$8.57 million-$0.77-$0.8610.78%
2017-06-302017-08-09$8.51 million-$0.80-$0.9111.81%
2017-03-312017-05-10$3.63 million-$1.00-$0.95-5.11%
2016-12-312017-02-23$1.28 million-$1.22-$1.230.7%
2016-09-302016-11-08$N/A-$1.24-$1.21-2.12%
2016-06-302016-08-08$N/A-$1.17-$0.96-21.88%
2016-03-312016-05-05$N/A-$0.92-$0.87-5.26%
2015-12-312016-02-19$N/A-$0.87-$0.66-31.48%
2015-09-302015-11-06$N/A-$0.63-$0.675.97%
2015-06-302015-08-07$N/A-$0.74-$0.65-13.85%
2015-03-312015-05-08$N/A-$0.70-$0.68-2.94%
2014-12-312015-03-13$N/A-$0.71-$0.7910.13%
2014-09-302014-11-06$N/A-$0.66-$0.7714.29%
2014-06-302014-08-04$N/A-$0.78-$0.74-5.41%
2014-03-312014-05-08$N/A-$0.74-$0.67-10.45%
2013-12-312014-03-05$N/A-$0.75-$0.53-41.51%
2013-09-302013-11-12$N/A-$0.80-$0.9313.98%
2013-06-302013-08-08$N/A-$1.00-$0.80-25%
2013-03-312013-05-10$N/A-$0.80-$0.60-33.33%
2012-12-312013-03-01$-599000-$0.60-$0.40-50%
2012-09-302012-11-05$N/A-$0.40-$0.20-100%
2012-06-302012-08-02$N/A-$0.40-$0.400%
2012-03-312012-05-10$N/A-$0.49
2011-12-312012-03-26$646000-$0.71
2011-09-302011-11-07$-251000-$0.42
2011-06-302011-08-08$251000-$0.97
2011-03-312011-05-16$395000-$0.71
2010-12-312011-03-28$179000-$0.80
2010-09-302010-11-15$351000-$0.85
2010-06-302010-08-16$530000-$1.81
2010-03-312010-05-18$241000-$0.25
2009-12-312010-03-15$122000-$1.25
2009-09-302009-11-16$1.12 million-$0.78
2009-06-302009-08-04$14000-$2.54
2009-03-312009-05-14$8000-$2.00-$2.000%
2008-12-312009-03-31$21000-$2.60-$4.1036.59%
2008-09-302008-11-05$64000-$4.00-$4.204.76%
2008-06-302008-08-14$151000-$4.00-$4.409.09%
2008-03-312008-05-15$133000-$4.40-$4.30-2.33%
2007-12-312008-03-13$132000-$5.00-$3.50-42.86%
2007-09-302007-11-13$120000-$3.00-$3.000%
2007-06-302007-08-01$160000-$3.80-$12.8070.31%
2007-03-312007-05-08$N/A-$18.93
2006-12-312007-03-07$N/A-$17.60-$11.20-57.14%
2006-09-302006-11-07$N/A-$12.00-$14.4016.67%
2006-06-302006-08-08$N/A-$14.41
2006-03-312006-05-10$N/A$60.59
2005-12-312006-03-15$1.44 million-$8.28
2005-09-302005-11-02$1.34 million-$5.55
2005-06-302005-08-08$1.25 million-$8.31
2005-03-312005-05-10$1.36 million-$4.01
2004-12-312005-03-10$1.48 million-$7.22
2004-09-302004-11-15$1.46 million-$6.05
2004-06-302004-08-12$1.28 million-$9.28
2004-03-312004-04-28$1.18 million-$9.60-$4.80-100%
2003-12-312004-03-12$1.36 million-$5.34
2003-09-302003-11-07$1.27 million-$4.11
2003-06-302003-08-04$1.12 million-$7.52
2003-03-312003-05-05$1.11 million$0.13
2002-09-302002-09-30$1.04 million-$4.12
2002-06-302002-06-30$967000-$5.85
2002-03-312002-03-31$952000-$3.95
2001-09-302001-09-30$969000$5.88
2001-06-302001-06-30$1000000-$4.72
2001-03-312001-03-31$971000-$4.44
2000-09-302000-11-03$887000-$2.40-$4.8050%
2000-06-302000-08-15$869000-$4.00$1.60-350%
2000-03-312000-05-15$730000$0.80
1999-09-301999-11-11$2.40$1.6050%
1999-06-301999-07-29$1.60$4.40-63.64%
1999-03-311999-05-06$1.60$5.60-71.43%
1998-12-311999-03-04$4.80$7.20-33.33%
1998-09-301998-11-04$2.40$4.80-50%
1998-06-301998-07-30$0.80
1998-03-311998-03-31$0.11

Heron Therapeutics, Inc (HRTX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Heron Therapeutics, Inc (HRTX) Chart:

Heron Therapeutics, Inc (HRTX) News:

Below you will find a list of latest news for Heron Therapeutics, Inc (HRTX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Heron Therapeutics, Inc (HRTX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-07-180.51.65CALL0 2765.59TRUE00
2025-07-1810CALL0 0240.16TRUE00
2025-07-181.50.7CALL0 63252.95TRUE00
2025-07-1820.24CALL0 12329TRUE00
2025-07-1830.05CALL0 32137.07FALSE00
2025-07-1840CALL0 0429.72FALSE00
2025-07-1850.05CALL0 100483.45FALSE00
2025-07-180.50PUT0 0390.04FALSE00
2025-07-1810PUT0 0617.1FALSE00
2025-07-181.50PUT0 0469.52FALSE00
2025-07-1820.08PUT0 16056.05FALSE00
2025-07-1830PUT0 086.87TRUE00
2025-07-1840PUT0 0196.8TRUE00
2025-07-1850PUT0 0217.84TRUE00
2025-08-150.50CALL0 0577.69TRUE00
2025-08-1510CALL0 0314.09TRUE00
2025-08-151.50CALL0 0115.84TRUE00
2025-08-1520.4CALL30 20100.77TRUE00
2025-08-1530CALL0 0177.4FALSE00
2025-08-1540CALL0 0244.92FALSE00
2025-08-1550CALL0 0280.2FALSE00
2025-08-150.50PUT0 0823.01FALSE00
2025-08-1510PUT0 0410.48FALSE00
2025-08-151.50PUT0 0243.61FALSE00
2025-08-1520PUT0 099.34FALSE00
2025-08-1530PUT0 0109.78TRUE00
2025-08-1540PUT0 0195.83TRUE00
2025-08-1550PUT0 0211.93TRUE00
2025-09-190.51.69CALL1 127199.65TRUE1.690
2025-09-1911.18CALL0 180137.55TRUE00
2025-09-191.50.8CALL0 54186.89TRUE00
2025-09-1920.4CALL1 698276.2TRUE0.40
2025-09-1930.09CALL12 1241573.62FALSE-0.01-0.1
2025-09-1940.05CALL0 20078.25FALSE00
2025-09-1950CALL0 75245.11FALSE00
2025-09-1960.05CALL0 5114.19FALSE00
2025-09-190.50PUT0 0633.67FALSE00
2025-09-1910PUT0 0315.94FALSE00
2025-09-191.50PUT0 2125.93FALSE00
2025-09-1920.31PUT0 6583.61FALSE00
2025-09-1930PUT0 4961.86TRUE00
2025-09-1940PUT0 0115.52TRUE00
2025-09-1950PUT0 0194.1TRUE00
2025-09-1960PUT0 0170.53TRUE00
2025-12-190.51.62CALL0 43230.71TRUE00
2025-12-1911.1CALL0 310135.85TRUE00
2025-12-191.50.75CALL0 100891.5TRUE00
2025-12-1920.51CALL0 16587.75TRUE00
2025-12-1930.19CALL7 25969.51FALSE-0.01-0.05
2025-12-1940.15CALL0 5370.27FALSE00
2025-12-1950CALL0 103134.8FALSE00
2025-12-190.50PUT0 0445.14FALSE00
2025-12-1910PUT0 0156.9FALSE00
2025-12-191.50PUT0 0107.79FALSE00
2025-12-1920PUT0 20059.81FALSE00
2025-12-1931PUT100 372.9TRUE10
2025-12-1940PUT0 0110.94TRUE00
2025-12-1950PUT0 0110.73TRUE00

Latest HRTX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$2.315
Jun 13, 2022 7:59 PM EST75$2.315
Jun 13, 2022 7:59 PM EST9$2.315
Jun 13, 2022 7:59 PM EST100$2.32
Jun 13, 2022 7:59 PM EST74$2.32

Heron Therapeutics, Inc (HRTX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020031058/0001564590-20-031058-index.htm
2018-07-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/818033/000000000018021777/0000000000-18-021777-index.htm
2018-08-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/818033/000000000018026157/0000000000-18-026157-index.htm
2018-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000003877718000193/0000038777-18-000193-index.htm
2019-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000003877719000002/0000038777-19-000002-index.htm
2020-02-04SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000003877720000026/0000038777-20-000026-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000021545719006786/0000215457-19-006786-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000031506619001066/0000315066-19-001066-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000031506620001040/0000315066-20-001040-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000031506620001651/0000315066-20-001651-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000083423720005426/0000834237-20-005426-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000090221919000304/0000902219-19-000304-index.htm
2020-01-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000090221920000046/0000902219-20-000046-index.htm
2019-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000093247119005421/0000932471-19-005421-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000110465920018119/0001104659-20-018119-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000110465920021753/0001104659-20-021753-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000114420419007225/0001144204-19-007225-index.htm
2018-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518201200/0001193125-18-201200-index.htm
2018-06-258-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518202464/0001193125-18-202464-index.htm
2018-06-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/818033/000119312518202508/0001193125-18-202508-index.htm
2018-06-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/818033/000119312518205702/0001193125-18-205702-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518207684/0001193125-18-207684-index.htm
2018-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/818033/000119312518231460/0001193125-18-231460-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518242059/0001193125-18-242059-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000119312518242064/0001193125-18-242064-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518320928/0001193125-18-320928-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000119312518320941/0001193125-18-320941-index.htm
2018-12-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312518361750/0001193125-18-361750-index.htm
2019-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519001151/0001193125-19-001151-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519003247/0001193125-19-003247-index.htm
2019-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519028339/0001193125-19-028339-index.htm
2019-02-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519032236/0001193125-19-032236-index.htm
2019-02-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519047774/0001193125-19-047774-index.htm
2019-02-2210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/818033/000119312519047780/0001193125-19-047780-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519051944/0001193125-19-051944-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519070125/0001193125-19-070125-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519093695/0001193125-19-093695-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/818033/000119312519122529/0001193125-19-122529-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/818033/000119312519122544/0001193125-19-122544-index.htm
2019-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519130962/0001193125-19-130962-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519142329/0001193125-19-142329-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000119312519142333/0001193125-19-142333-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519146046/0001193125-19-146046-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519152334/0001193125-19-152334-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519176468/0001193125-19-176468-index.htm
2019-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519195218/0001193125-19-195218-index.htm
2019-10-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/818033/000119312519261632/0001193125-19-261632-index.htm
2019-10-07424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/818033/000119312519263773/0001193125-19-263773-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000119312519264451/0001193125-19-264451-index.htm
2018-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118039348/0001209191-18-039348-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2018-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118050601/0001209191-18-050601-index.htm
2018-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118050997/0001209191-18-050997-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118053532/0001209191-18-053532-index.htm
2018-11-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118057056/0001209191-18-057056-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063286/0001209191-18-063286-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063346/0001209191-18-063346-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063347/0001209191-18-063347-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063348/0001209191-18-063348-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063349/0001209191-18-063349-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063350/0001209191-18-063350-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063351/0001209191-18-063351-index.htm
2018-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919118063353/0001209191-18-063353-index.htm
2019-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119010097/0001209191-19-010097-index.htm
2019-05-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119027143/0001209191-19-027143-index.htm
2019-05-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119030201/0001209191-19-030201-index.htm
2019-05-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119032198/0001209191-19-032198-index.htm
2019-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119042303/0001209191-19-042303-index.htm
2019-10-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119051412/0001209191-19-051412-index.htm
2019-10-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119051413/0001209191-19-051413-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119052611/0001209191-19-052611-index.htm
2019-10-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119052612/0001209191-19-052612-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119052702/0001209191-19-052702-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119058834/0001209191-19-058834-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061762/0001209191-19-061762-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061786/0001209191-19-061786-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061788/0001209191-19-061788-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061789/0001209191-19-061789-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061794/0001209191-19-061794-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061795/0001209191-19-061795-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061796/0001209191-19-061796-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919119061798/0001209191-19-061798-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120009590/0001209191-20-009590-index.htm
2020-02-145Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120009728/0001209191-20-009728-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120025019/0001209191-20-025019-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120025021/0001209191-20-025021-index.htm
2020-05-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120026627/0001209191-20-026627-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054905/0001209191-20-054905-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054906/0001209191-20-054906-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054907/0001209191-20-054907-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054908/0001209191-20-054908-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054909/0001209191-20-054909-index.htm
2020-10-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054910/0001209191-20-054910-index.htm
2020-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120054914/0001209191-20-054914-index.htm
2020-10-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/818033/000120919120055390/0001209191-20-055390-index.htm
2018-09-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/818033/000121465918006019/0001214659-18-006019-index.htm
2020-01-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/818033/000121465920000176/0001214659-20-000176-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000127417318000093/0001274173-18-000093-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000127417319000052/0001274173-19-000052-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/818033/000127417320000028/0001274173-20-000028-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019028536/0001564590-19-028536-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459019028537/0001564590-19-028537-index.htm
2019-08-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/818033/000156459019028818/0001564590-19-028818-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019032608/0001564590-19-032608-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036000/0001564590-19-036000-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036090/0001564590-19-036090-index.htm
2019-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036093/0001564590-19-036093-index.htm
2019-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019036139/0001564590-19-036139-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019037287/0001564590-19-037287-index.htm
2019-10-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019038027/0001564590-19-038027-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019042630/0001564590-19-042630-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459019042638/0001564590-19-042638-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019045076/0001564590-19-045076-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019046060/0001564590-19-046060-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459019046547/0001564590-19-046547-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020000917/0001564590-20-000917-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020005303/0001564590-20-005303-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020007971/0001564590-20-007971-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/818033/000156459020007973/0001564590-20-007973-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/818033/000156459020018187/0001564590-20-018187-index.htm
2020-04-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/818033/000156459020018204/0001564590-20-018204-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020021571/0001564590-20-021571-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459020021575/0001564590-20-021575-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020025913/0001564590-20-025913-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020028307/0001564590-20-028307-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020029788/0001564590-20-029788-index.htm
2020-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020031058/0001564590-20-031058-index.htm
2020-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020032445/0001564590-20-032445-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020033338/0001564590-20-033338-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020036807/0001564590-20-036807-index.htm
2020-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459020036822/0001564590-20-036822-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020036849/0001564590-20-036849-index.htm
2020-09-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020042727/0001564590-20-042727-index.htm
2020-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020043657/0001564590-20-043657-index.htm
2020-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020044749/0001564590-20-044749-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020046256/0001564590-20-046256-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/818033/000156459020050909/0001564590-20-050909-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/818033/000156459020050911/0001564590-20-050911-index.htm

Heron Therapeutics, Inc (HRTX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Heron Therapeutics, Inc (HRTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 29%
Institutional Ownership: 10143%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-07-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell100.0038.853,885.000.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-10-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell6,000.0032.07192,433.200.00https://www.sec.gov/Archives/edgar/data/818033/000120919118053532/0001209191-18-053532-index.htm
2018-11-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell494.0030.6215,124.950.00https://www.sec.gov/Archives/edgar/data/818033/000120919118057056/0001209191-18-057056-index.htm
2019-05-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell1,109.0018.8620,918.070.00https://www.sec.gov/Archives/edgar/data/818033/000120919119027143/0001209191-19-027143-index.htm
2019-11-29KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell24,000.0026.00624,000.000.00https://www.sec.gov/Archives/edgar/data/818033/000120919119058834/0001209191-19-058834-index.htm
2020-05-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell1,158.0013.9716,175.750.00https://www.sec.gov/Archives/edgar/data/818033/000120919120026627/0001209191-20-026627-index.htm
2018-07-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentSell5,900.0037.51221,293.66100.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-06-21Barry D QuartChief Executive OfficerBuy50,000.009.05452,500.00119,600.00https://www.sec.gov/Archives/edgar/data/818033/000120919118039348/0001209191-18-039348-index.htm
2018-07-02ROBERT HOFFMANCFO & SVP, FinanceSell1,060.0038.8041,123.021,280.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2019-05-22JOHN POYHONENDirectorBuy3,000.0017.5552,650.0013,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919119032198/0001209191-19-032198-index.htm
2018-06-29Robert RosenPresidentBuy129,469.007.20932,176.80132,109.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2019-05-15Waage ChristianDirectorBuy1,400.0018.0425,261.741,400.00https://www.sec.gov/Archives/edgar/data/818033/000120919119030201/0001209191-19-030201-index.htm
2019-10-03JOHN POYHONENEVP, Chief Commercial OfficerBuy5,143.0017.5090,002.5018,143.00https://www.sec.gov/Archives/edgar/data/818033/000120919119052611/0001209191-19-052611-index.htm
2018-07-02ROBERT HOFFMANCFO & SVP, FinanceSell28,940.0038.151,104,107.302,340.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2019-11-29KIMBERLY MANHARDExecutive VP, Drug DevelopmentBuy24,000.0013.00312,000.0024,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919119058834/0001209191-19-058834-index.htm
2018-06-29Robert RosenPresidentSell2,112.0041.3987,415.472,640.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-07-02Robert RosenPresidentSell3,400.0038.75131,764.962,640.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-07-02ROBERT HOFFMANCFO & SVP, FinanceBuy30,000.0015.30459,000.0031,280.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041385/0001209191-18-041385-index.htm
2018-06-29Robert RosenPresidentSell51,696.0040.172,076,597.304,752.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-06-29Robert RosenPresidentSell75,661.0039.142,961,121.8656,448.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2019-10-04KEVIN C TANGDirectorBuy285,714.0017.504,999,995.005,799,810.00https://www.sec.gov/Archives/edgar/data/818033/000120919119052702/0001209191-19-052702-index.htm
2018-09-12KEVIN C TANGDirectorSell2,695,000.0035.7596,346,250.005,830,215.00https://www.sec.gov/Archives/edgar/data/818033/000120919118050601/0001209191-18-050601-index.htm
2018-07-02KIMBERLY MANHARDExecutive VP, Drug DevelopmentBuy6,000.0013.0078,000.006,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041386/0001209191-18-041386-index.htm
2018-10-01KIMBERLY MANHARDExecutive VP, Drug DevelopmentBuy6,000.0013.0078,000.006,000.00https://www.sec.gov/Archives/edgar/data/818033/000120919118053532/0001209191-18-053532-index.htm
2018-07-02Robert RosenPresidentSell92,131.0038.133,512,918.186,040.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm
2018-06-21Barry D QuartChief Executive OfficerSell50,000.0039.051,952,500.0069,600.00https://www.sec.gov/Archives/edgar/data/818033/000120919118039348/0001209191-18-039348-index.htm
2018-09-14Barry D QuartChief Executive OfficerBuy19,675.007.20141,660.0089,275.00https://www.sec.gov/Archives/edgar/data/818033/000120919118050997/0001209191-18-050997-index.htm
2019-10-03Barry D QuartChief Executive OfficerBuy4,571.0017.5079,992.5094,652.00https://www.sec.gov/Archives/edgar/data/818033/000120919119052612/0001209191-19-052612-index.htm
2018-07-02Robert RosenPresidentBuy95,531.007.20687,823.2098,171.00https://www.sec.gov/Archives/edgar/data/818033/000120919118041384/0001209191-18-041384-index.htm